Global Pharma, Biotech & Diagnostics Collaborative R&D Partnering Terms and Agreements Report 2012-2018

Dublin, March 07, 2018 -- The "Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2012 to 2018.

There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.

There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

This report contains a comprehensive listing of all collaborative R&D deals announced since 2012 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.

In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

• In-depth understanding of collaborative R&D deal trends since 2012
• Analysis of the structure of collaborative R&D agreements with numerous real life case studies
• Comprehensive listing of over 4,500 collaborative R&D deals since 2012, together with deal terms, value and press release
• Comprehensive access to actual collaborative R&D contracts entered into by the world's life science companies
• Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
• Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 includes:

• Trends in collaborative R&D dealmaking in the biopharma industry since 2012
• Analysis of collaborative R&D deal structure
• Case studies of real-life collaborative R&D deals
• Comprehensive listing of over 4,500 collaborative R&D deals since 2012
• Access to collaborative R&D contract documents
• Key financial benchmarks for headline, upfront, milestone and royalty rates
• The leading collaborative R&D deals by value since 2012
• Most active collaborative R&D dealmakers since 2012
• The leading collaborative R&D partnering resources

Available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaborative R&D dealmaking

2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2012
2.7. The future of collaborative R&D deals

Chapter 3 - Overview of collaborative R&D deal structure

3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.4. Collaborative R&D as part of a wider alliance agreement

Chapter 4 - Leading collaborative R&D deals

4.1. Introduction
4.2. Top collaborative R&D deals by value

Chapter 5 - Top 50 most active collaborative R&D dealmakers

5.1. Introduction
5.2. Top 50 most active collaborative R&D dealmakers

Chapter 6 - Collaborative R&D deal term financials

6.1. Introduction
6.2. Collaborative R&D partnering headline values
6.3. Collaborative R&D deal upfront payments
6.4. Collaborative R&D deal milestone payments
6.5. Collaborative R&D royalty rates

Chapter 7 - Collaborative R&D contract directory 2012 - 2018

7.1. Introduction
7.2. Collaborative R&D deals with contracts 2012 to 2018

Companies Featured

• Abbott
• Abbvie
• Actavis
• Amgen
• Astellas
• AstraZeneca
• Baxter
• Bayer
• Biogen Idec
• BMS
• Celgene
• Eisai
• Eli Lilly
• Gilead
• GSK
• J&J
• Kyowa Hakko
• Merck
• Mitsubishi
• Mylan
• Novartis
• Pfizer
• Roche
• Sanofi
• Shire
• Takeda
• Teva
• Valeant

For more information about this report visit https://www.researchandmarkets.com/research/l4z62s/global_pharma?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biotechnology, Pharmaceuticals, Diagnostics